Sovaldi, Gilead’s oral inhibitor used to treat chronic hepatitis C, costs 58,980 yuan ($8,938) for a 12-week supply in China — which is only one-fifth of its current price in the U.S. market.
When Gilead’s drug was first launched in the U.S. in 2013, it cost a widely-criticized $84,000 per 12-week course, which equates to $1,000 per pill. However, with increased competition and pressure from payers, Sovaldi’s average price has decreased significantly to roughly $44,700 per course, according to the report.
The biopharmaceutical company has a history of cutting the price of Sovaldi when launching the drug in regions outside the U.S. For example, to sell in India, Gilead slashed the price from $1,000 per pill to roughly $4 per pill.
Gilead remains under pressure to export Sovaldi as sales of the hepatitis C drug have stagnated in the U.S., according to the report.
More articles on supply chain:
6 must-reads for supply chain leaders this week
Roche sues Pfizer to prevent a biosimilar from entering US market
4 ways the FDA is addressing the saline bag shortage
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
